Cell Penetrating Elastin-like Polypeptides for Therapeutic Peptide Delivery

Overview

Journal Adv Drug Deliv Rev

Specialty Pharmacology

Date 2010 May 19

PMID 20478348

Citations 42

Authors

Gene L Bidwell 3rd

Drazen Raucher

Affiliations

Soon will be listed here.

Abstract

Current treatment of solid tumors is limited by side effects that result from the non-specific delivery of drugs to the tumor site. Alternative targeted therapeutic approaches for localized tumors would significantly reduce systemic toxicity. Peptide therapeutics are a promising new strategy for targeted cancer therapy because of the ease of peptide design and the specificity of peptides for their intracellular molecular targets. However, the utility of peptides is limited by their poor pharmacokinetic parameters and poor tissue and cellular membrane permeability in vivo. This review article summarizes the development of elastin-like polypeptide (ELP) as a potential carrier for thermally targeted delivery of therapeutic peptides (TP), and the use of cell penetrating peptides (CPP) to enhance the intracellular delivery of the ELP-fused TPs. CPP-fused ELPs have been used to deliver a peptide inhibitor of c-Myc function and a peptide mimetic of p21 in several cancer models in vitro, and both polypeptides are currently yielding promising results in in vivo models of breast and brain cancer.

Citing Articles

An Elastin-like Polypeptide-fusion peptide targeting capsid-tegument interface as an antiviral against cytomegalovirus infection.

Beeton K, Mitra D, Akinleye A, Howell J, Yu C, Bidwell 3rd G Sci Rep. 2024; 14(1):10253.

PMID: 38704431 PMC: 11069587. DOI: 10.1038/s41598-024-60691-6.

Elastin-like polypeptide delivery of anti-inflammatory peptides to the brain following ischemic stroke.

Howell J, Gaouette N, Lopez M, Burke S, Perkins E, Bidwell 3rd G bioRxiv. 2023; .

PMID: 36993686 PMC: 10055169. DOI: 10.1101/2023.03.15.532834.

Application of bioengineered elastin-like polypeptide-based system for targeted gene delivery in tumor cells.

Yi A, Sim D, Lee S, Sarangthem V, Park R Biomater Biosyst. 2023; 6:100050.

PMID: 36824163 PMC: 9934475. DOI: 10.1016/j.bbiosy.2022.100050.

Therapeutic Effect of IL-4 Receptor-Targeting Pro-Apoptotic Peptide (AP1-ELP-KLAK) in Glioblastoma Tumor Model.

Sarangthem V, Yi A, Kim Y, Rehemtulla A, Lee B, Jeon Y Int J Nanomedicine. 2021; 16:5039-5052.

PMID: 34335025 PMC: 8318221. DOI: 10.2147/IJN.S316388.

Machine learning to determine optimal conditions for controlling the size of elastin-based particles.

Cobb J, Engel A, Seale M, Janorkar A Sci Rep. 2021; 11(1):6343.

PMID: 33737605 PMC: 7973436. DOI: 10.1038/s41598-021-85601-y.

References

Shamji M, Chen J, Friedman A, Richardson W, Chilkoti A, Setton L . Synthesis and characterization of a thermally-responsive tumor necrosis factor antagonist. J Control Release. 2008; 129(3):179-86. PMC: 2637771. DOI: 10.1016/j.jconrel.2008.04.021. View

Mattock H, Lane D, Warbrick E . Inhibition of cell proliferation by the PCNA-binding region of p21 expressed as a GFP miniprotein. Exp Cell Res. 2001; 265(2):234-41. DOI: 10.1006/excr.2001.5160. View

Massodi I, Moktan S, Rawat A, Bidwell 3rd G, Raucher D . Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier. Int J Cancer. 2009; 126(2):533-44. PMC: 2795124. DOI: 10.1002/ijc.24725. View

Rousselle C, Clair P, Lefauconnier J, Kaczorek M, Scherrmann J, Temsamani J . New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol. 2000; 57(4):679-86. DOI: 10.1124/mol.57.4.679. View

Chen I, Akamatsu M, Smith M, Lung F, Duba D, Roller P . Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction. Oncogene. 1996; 12(3):595-607. View

Vives E, Richard J, Rispal C, Lebleu B . TAT peptide internalization: seeking the mechanism of entry. Curr Protein Pept Sci. 2003; 4(2):125-32. DOI: 10.2174/1389203033487306. View

Feyerabend T, Steeves R, Wiedemann G, Richter E, Robins H . Rationale and clinical status of local hyperthermia, radiation, and chemotherapy in locally advanced malignancies. Anticancer Res. 1997; 17(4B):2895-7. View

Warbrick E, Lane D, Glover D, Cox L . A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol. 1995; 5(3):275-82. DOI: 10.1016/s0960-9822(95)00058-3. View

MacKay J, Chen M, McDaniel J, Liu W, Simnick A, Chilkoti A . Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat Mater. 2009; 8(12):993-9. PMC: 2862348. DOI: 10.1038/nmat2569. View

10.

Draeger L, Mullen G . Interaction of the bHLH-zip domain of c-Myc with H1-type peptides. Characterization of helicity in the H1 peptides by NMR. J Biol Chem. 1994; 269(3):1785-93. View

11.

Feuerstein B, Pattabiraman N, Marton L . Spermine-DNA interactions: a theoretical study. Proc Natl Acad Sci U S A. 1986; 83(16):5948-52. PMC: 386414. DOI: 10.1073/pnas.83.16.5948. View

12.

Pelengaris S, Khan M, Evan G . c-MYC: more than just a matter of life and death. Nat Rev Cancer. 2002; 2(10):764-76. DOI: 10.1038/nrc904. View

13.

Bakic M, Chan D, Freireich E, Marton L, Zwelling L . Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells. Cancer Res. 1987; 47(24 Pt 1):6437-43. View

14.

Massodi I, Thomas E, Raucher D . Application of thermally responsive elastin-like polypeptide fused to a lactoferrin-derived peptide for treatment of pancreatic cancer. Molecules. 2009; 14(6):1999-2015. PMC: 6254221. DOI: 10.3390/molecules14061999. View

15.

Chen T, Bae Y, Furgeson D . Intelligent biosynthetic nanobiomaterials (IBNs) for hyperthermic gene delivery. Pharm Res. 2007; 25(3):683-91. DOI: 10.1007/s11095-007-9382-5. View

16.

Gupta B, Levchenko T, Torchilin V . Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev. 2005; 57(4):637-51. DOI: 10.1016/j.addr.2004.10.007. View

17.

Vives E, Schmidt J, Pelegrin A . Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta. 2008; 1786(2):126-38. DOI: 10.1016/j.bbcan.2008.03.001. View

18.

Thyberg J . Caveolae and cholesterol distribution in vascular smooth muscle cells of different phenotypes. J Histochem Cytochem. 2002; 50(2):185-95. DOI: 10.1177/002215540205000206. View

19.

Jain R . Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng. 2001; 1:241-63. DOI: 10.1146/annurev.bioeng.1.1.241. View

20.

Lipka E, Crison J, Amidon G . Transmembrane transport of peptide type compounds: prospects for oral delivery. J Control Release. 1996; 39(2-3):121-9. DOI: 10.1016/0168-3659(95)00145-x. View